MCID: HPT003
MIFTS: 59

Hepatitis a malady

Categories: Infectious diseases, Skin diseases, Liver diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Immune diseases

Aliases & Classifications for Hepatitis a

Aliases & Descriptions for Hepatitis a:

Name: Hepatitis a 12 41 42 14 69
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12549
MeSH 42 D006506
NCIt 47 C3096
SNOMED-CT 64 154347003 40468003
ICD10 33 B15.0 B15.9
UMLS 69 C0019159

Summaries for Hepatitis a

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. hepatitis is an inflammation of the liver. one type, hepatitis a, is caused by the hepatitis a virus (hav). the disease spreads through contact with an infected person's stool. you can get it from eating food made by an infected person who did not wash their hands after using the bathroom drinking untreated water or eating food washed in untreated water putting into your mouth a finger or object that came into contact with an infected person's stool having close contact with an infected person, such as through sex or caring for someone who is ill most people do not have any symptoms. if you do have symptoms, you may feel as if you have the flu. you may also have yellowish eyes and skin, called jaundice. a blood test will show if you have hav. hav usually gets better in a few weeks without treatment. however, some people can have symptoms for up to 6 months. your doctor may suggest medicines to help relieve your symptoms. the hepatitis a vaccine can prevent hav. good hygiene can also help. wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. international travelers should be careful about drinking tap water. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to granulomatous hepatitis and influenza, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Immune response IL-23 signaling pathway. The drugs Aluminum hydroxide and Cyclosporine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotype is hematopoietic system.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted_by ingestion of contaminated food or water, or transmitted_by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 71 Hepatitis A (formerly known as infectious hepatitis) is an infectious disease of the liver caused by the... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 299)
id Related Disease Score Top Affiliating Genes
1 granulomatous hepatitis 29.6 F2 F3 SERPINC1
2 influenza 29.4 F2 F3 SERPINC1
3 rift valley fever 29.0 ALB IFNG TNF
4 klinefelter's syndrome 28.8 AFP ALB SERPINA1
5 hepatitis 11.6
6 liver disease 10.8
7 fatty liver disease 10.6
8 congenital dyserythropoietic anemia 10.3 ALB TNF
9 nondystrophic myotonia 10.3 ALB F2
10 familial progressive hyperpigmentation 10.3 F2 GPT
11 bladder sarcoma 10.2 ALB GPT TNF
12 colloid adenoma 10.2 ALB CD4
13 female infertility of uterine origin 10.2 ALB F2 GPT
14 kohler's disease 10.2 ALB F2 GPT
15 acute monocytic leukemia 10.2 ALB F2 GPT
16 hemopneumothorax 10.2 F2 IFNA2
17 blue color blindness 10.2 CD4 IFNA2
18 stromal corneal pigmentation 10.2 CD4 IFNA2
19 pyelitis 10.2 ALB F2 GPT
20 parovarian cyst 10.2 F2 TNF
21 fallopian tube leiomyosarcoma 10.2 ALB F2 GPT
22 stocco dos santos syndrome 10.2 IFNG TNF
23 gastrointestinal adenoma 10.2 ALB F2 GPT
24 infiltrating ureter transitional cell carcinoma 10.2 ALB F2 TNF
25 heterophyiasis 10.2 CD4 GPT
26 autosomal dominant deafness-onychodystrophy syndrome 10.2 IFNG TNF
27 maxillary sinusitis 10.2 F2 GPT IFNA2
28 nephrocalcinosis 10.2 ALB CD4
29 rosacea 10.2 ALB GPT IFNG
30 isolated growth hormone deficiency 10.2 ALB GPT IFNG
31 rickettsia parkeri spotted fever 10.2 HAVCR2 IFNG
32 hemarthrosis 10.2 F2 F3
33 hypertropia 10.2 ALB IFNG TNF
34 calcinosis 10.2 ALB HAVCR1 TNF
35 plummer's disease 10.2 ALB IFNG TNF
36 pharynx carcinoma in situ 10.2 ALB F2
37 vogt-koyanagi-harada disease 10.1 F3 GPT TNF
38 mansonelliasis 10.1 ALB IFNG TNF
39 viral hepatitis 10.1
40 liver inflammatory pseudotumor 10.1 ALB IFNG TNF
41 distal trisomy 14q 10.1 IFNG TNF
42 pigmentation disease 10.1 ALB IFNG TNF
43 alpha-2-macroglobulin deficiency 10.1 F2 F3
44 pulpitis 10.1 F2 IFNG TNF
45 uterine ligament clear cell adenocarcinoma 10.1 ALB IFNG TNF
46 vascular erectile tumor 10.1 F2 SERPINC1
47 chronic inflammatory demyelinating polyneuritis 10.1 ALB F2 F3
48 pulmonary eosinophilia 10.1 ALB IFNG TNF
49 miller-dieker lissencephaly syndrome 10.1 F2 SERPINC1
50 rete testis adenoma 10.1 AFP SERPINA1

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • joint pain
  • jaundice

UMLS symptoms related to Hepatitis a:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, icterus, nausea and vomiting, pruritus, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.23 CD4 F2 F3 GPT HAVCR2 IFNG

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 763)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
5
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
6
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
7
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
8
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
9
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
10
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
11
Isoniazid Approved Phase 4,Phase 3,Phase 2 54-85-3 3767
12
Pyrazinamide Approved Phase 4 98-96-4 1046
13
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
14
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
15
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
16
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
17
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
18
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
19
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
20
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
21
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
22
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
23
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
24
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
25
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
26
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
27
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 83-43-2 6741
28
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-24-8 5755
29
Ethiodized oil Approved Phase 4,Phase 3,Phase 2 8008-53-5
30
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
31
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
32
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
33
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
34
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6493-05-6 4740
35
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
36
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
37
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128-13-2 31401
38
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
39
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
40
Insulin Glargine Approved Phase 4 160337-95-1
41
Insulin-glulisine Approved Phase 4 207748-29-6
42
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
43
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
44
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
45
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
46
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1190307-88-0 45375808
47
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1 1256388-51-8 67505836
48
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
49
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
50
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7

Interventional clinical trials:

(show top 50) (show all 3913)
id Name Status NCT ID Phase
1 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
2 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
3 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
4 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
5 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
6 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4
7 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4
8 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
9 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
10 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
11 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Unknown status NCT01488526 Phase 4
12 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
13 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4
14 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4
15 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
16 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4
17 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4
18 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4
19 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
20 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4
21 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4
22 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4
23 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4
24 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4
25 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4
26 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4
27 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
28 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
29 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4
30 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4
31 Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B Unknown status NCT01926288 Phase 4
32 A Two-year Study of Telbivudine in HBeAg Negative Hepatitis Unknown status NCT01521975 Phase 4
33 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4
34 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4
35 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4
36 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4
37 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4
38 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4
39 Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B Unknown status NCT01913431 Phase 4
40 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4
41 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4
42 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4
43 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4
44 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4
45 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
46 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4
47 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4
48 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4
49 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
50 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

MalaCards organs/tissues related to Hepatitis a:

39
Liver, Testes, Kidney, Skin, Eye, T Cells, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

18
Liver

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 902)
id Title Authors Year
1
A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine. ( 28060048 )
2017
2
Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression. ( 27986562 )
2017
3
Digital RT-PCR method for hepatitis A virus and norovirus quantification in soft berries. ( 27960104 )
2017
4
Physician Knowledge and Attitudes about Hepatitis A and Current Practices Regarding Hepatitis A Vaccination Delivery. ( 28089593 )
2017
5
Persistence of Antibody to Hepatitis A Virus 20 Years After Receipt of Hepatitis A Vaccine in Alaska. ( 28092416 )
2017
6
A large prolonged outbreak of hepatitis A associated with consumption of frozen berries, Italy, 2013-14. ( 28086079 )
2017
7
Elimination of representative contaminant candidate list viruses, coxsackievirus, echovirus, hepatitis A virus, and norovirus, from water by coagulation processes. ( 28011355 )
2017
8
Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site. ( 28074040 )
2017
9
Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A. ( 26347518 )
2016
10
The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. ( 27724882 )
2016
11
Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran. ( 27110256 )
2016
12
Detection and molecular characterisation of Hepatitis A virus from Tunisian wastewater treatment plants with different secondary treatments. ( 27107113 )
2016
13
Healthy Donor Fecal Microbiota Transplantation in Steroid Ineligible Severe Alcoholic Hepatitis - A Pilot Study. ( 27816755 )
2016
14
Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups. ( 28013247 )
2016
15
Vaccination against Hepatitis A and B in Patients with Chronic Liver Disease and Type 2 Diabetes: Has Anything Changed? ( 27187614 )
2016
16
Cynomolgus monkeys (Macaca fascicularis) experimentally infected with B19V and hepatitis A virus: no evidence of the co-infection as a cause of acute liver failure. ( 27074255 )
2016
17
Pattern of Hepatitis A Virus Epidemiology in Nursing Students and Adherence to Preventive Measures at Two Training Wards of a University Hospital. ( 27195012 )
2016
18
Evidence of the circulation of hepatitis A virus, subgenotype IA, in environmental samples from Antioquia, Colombia. ( 27622803 )
2016
19
Biliary Secretion of Quasi-Enveloped Human Hepatitis A Virus. ( 27923925 )
2016
20
Solubility as a limiting factor for expression of hepatitis A virus proteins in insect cell-baculovirus system. ( 27581123 )
2016
21
Hepatitis A seroprevalence in public school children in Campos dos Goytacazes, Rio de Janeiro State, Brazil, prior to the introduction of the hepatitis A universal childhood vaccination. ( 27982290 )
2016
22
The Syrian refugees crisis brings challenges to the health authorities in Europe: hepatitis A virus is a case in point. ( 27194123 )
2016
23
Uptake and attitudes regarding hepatitis A vaccine among childcare centre staff, administrators, and parents. ( 27609536 )
2016
24
Projections of hepatitis A virus infection associated with flood events by 2020 and 2030 in Anhui Province, China. ( 27174415 )
2016
25
Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2A years after a single dose. ( 27494260 )
2016
26
A virus resonance light scattering sensor based on mussel-inspired molecularly imprinted polymers for high sensitive and high selective detection of Hepatitis A Virus. ( 27631682 )
2016
27
Therapeutic Efficacy and Safety of Paeoniae Radix Rubra Formulae in Relieving Hyperbilirubinemia Induced by Viral Hepatitis: A Meta-Analysis. ( 27047379 )
2016
28
Notes from the Field: Health Care-Associated Hepatitis A Outbreak - Texas, 2015. ( 27123787 )
2016
29
Effectiveness of hepatitis A vaccination as post-exposure prophylaxis. ( 27925847 )
2016
30
Comparison of concentration methods for detection of hepatitis A virus in water samples. ( 27535067 )
2016
31
Corticosteroids Versus Pentoxifylline for Severe Alcoholic Hepatitis: A Sequential Analysis of Randomized Controlled Trials. ( 27404293 )
2016
32
Hepatitis A virus vaccination in Iranian soldiers needs more attention. ( 27458517 )
2016
33
Risk factors for hospitalisation and associated costs among patients with hepatitis A associated with imported pomegranate arils, United States, 2013. ( 27156991 )
2016
34
Comprehensive profiling and characterization of cellular miRNAs in response to hepatitis A virus infection in human fibroblasts. ( 27590712 )
2016
35
Prevalence of hepatitis A across various countries in the Middle East, African and Eastern European countries. ( 27999652 )
2016
36
Bovine colostrum plus corticosteroids in treatment of severe alcoholic hepatitis: A prospective, proof of concept trial. ( 27727715 )
2016
37
Concentration and detection of hepatitis A virus and its indicator from artificial seawater using zeolite. ( 27150045 )
2016
38
Single-Dose Universal Hepatitis A Immunization in One Year Old Children in Argentina: High Prevalence of Protective Antibodies Up to 9 Years Following Vaccination. ( 27636725 )
2016
39
Effect of SIRS and sepsis on mortality in alcoholic hepatitis: A systematic review and meta-analysis. ( 27782895 )
2016
40
Viral hepatitis: A health problem that requires appropriate planning. ( 27131757 )
2016
41
A Review of Immunogenicity and Tolerability of Live Attenuated Hepatitis A Vaccine in Children. ( 27532370 )
2016
42
Acute Liver Failure Caused by Hepatitis A Virus with Dengue Coinfection. ( 27493466 )
2016
43
Hepatitis A Vaccine Response in Human Immunodeficiency Virus-infected Patients: The Interchangeability of Single Dose versus Double: A Prospective Look. ( 27942197 )
2016
44
MAVS-dependent host species range and pathogenicity of human hepatitis A virus. ( 27633528 )
2016
45
Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review. ( 27254289 )
2016
46
Viral hepatitis: A mouse model of hepatitis A virus infection. ( 27729656 )
2016
47
A Rare Association of Hepatitis A Virus Infection with Type-1 Diabetes. ( 27478582 )
2016
48
Phylogenetic analysis of a transfusion-transmitted hepatitis A outbreak. ( 27660174 )
2016
49
International Air Travel to Ohio, USA, and the Impact on Malaria, Influenza, and Hepatitis A. ( 27123365 )
2016
50
Are municipal solid waste collectors at increased risk of Hepatitis A Virus infection? A Greek cross-sectional study. ( 28011965 )
2016

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 ALB F2 F3 IFNA2 SERPINA1 SERPINC1
2
Show member pathways
12.33 CD4 F2 IFNG TNF
3 12.23 HAVCR1 HAVCR2 IFNG TNF
4
Show member pathways
12 ALB F2 IFNG TNF
5
Show member pathways
11.9 IFNA2 IFNG TNF
6 11.83 AFP ALB SERPINA1
7 11.7 F2 F3 SERPINA1 SERPINC1
8
Show member pathways
11.68 CD4 IFNG TNF
9 11.48 CD4 IFNG TNF
10 11.32 CD4 IFNA2 IFNG TNF
11 11.14 AFP ALB F2
12 10.81 CD4 IFNG TNF
13 10.81 CD4 IFNA2 IFNG TNF

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 AFP ALB F2 F3 IFNA2 IFNG
2 external side of plasma membrane GO:0009897 9.56 CD4 F2 IFNG TNF
3 endoplasmic reticulum lumen GO:0005788 9.43 AFP ALB CD4 F2 SERPINA1 SERPINC1
4 extracellular space GO:0005615 9.32 AFP ALB F2 F3 GPT IFNA2

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.81 AFP ALB SERPINA1 SERPINC1
2 cell surface receptor signaling pathway GO:0007166 9.78 CD4 F2 IFNA2 IFNG
3 cellular response to lipopolysaccharide GO:0071222 9.73 HAVCR2 IFNG TNF
4 negative regulation of gene expression GO:0010629 9.71 HAVCR2 IFNA2 IFNG TNF
5 positive regulation of protein phosphorylation GO:0001934 9.67 CD4 F2 IFNG TNF
6 positive regulation of T cell proliferation GO:0042102 9.63 CD4 HAVCR2 IFNG
7 humoral immune response GO:0006959 9.61 IFNA2 IFNG TNF
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.59 HAVCR2 TNF
9 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.58 IFNA2 IFNG
10 regulation of blood coagulation GO:0030193 9.58 F2 SERPINC1
11 positive regulation of osteoclast differentiation GO:0045672 9.57 IFNG TNF
12 positive regulation of chemokine production GO:0032722 9.55 HAVCR2 TNF
13 cellular protein metabolic process GO:0044267 9.55 AFP ALB F2 SERPINA1 SERPINC1
14 negative regulation of growth of symbiont in host GO:0044130 9.54 IFNG TNF
15 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.52 IFNG TNF
16 positive regulation of chemokine biosynthetic process GO:0045080 9.49 IFNG TNF
17 blood coagulation GO:0007596 9.35 F2 F3 IFNA2 SERPINA1 SERPINC1
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IFNG TNF
19 positive regulation of vitamin D biosynthetic process GO:0060557 9.26 IFNG TNF
20 hemostasis GO:0007599 8.92 F2 F3 SERPINA1 SERPINC1

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.92 F3 SERPINA1 SERPINC1 TNF

Sources for Hepatitis a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....